Showing results (51-60 of 97) with videos related to

Sort By:
Pageof 10
Clinical Pharmacology in Drug Development|February 28, 2019
A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched ControlsJafar Sadik B Shaik, Susan L Ford, Yu Lou, et al.
BMC Oral Health|July 3, 2025
Assessing the nutrient intake and diet quality of adults wearing dentures using the healthy eating indexGrace Gomez Felix Gomez, Huiping Xu, Lisa A Spence, et al.
British Journal of Cancer|February 10, 2017
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2Mary Ellen Moynahan, David Chen, Wei He, et al.
The Journal of Antimicrobial Chemotherapy|May 4, 2020
Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravirParul Patel, Zhengyu Xue, Karen S King, et al.
JAMA Oncology|August 18, 2016
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical TrialSarat Chandarlapaty, David Chen, Wei He, et al.
Cold Spring Harbor Molecular Case Studies|May 6, 2016
Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimusA Rose Brannon, Melissa Frizziero, David Chen, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 24, 2011
The use of rat lens explant cultures to study the mechanism of drug-induced cataractogenesisShruthi Sampath, Lee Anne McLean, Chiara Buono, et al.
The Lancet. Oncology|November 13, 2018
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort studyMartin H Voss, Albert Reising, Yuan Cheng, et al.
AIDS (London, England)|June 23, 2009
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatmentKimberly Y Smith, Parul Patel, Derek Fine, et al.
Cancer Medicine|July 20, 2024
Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignanciesCourtney D DiNardo, Rebecca Olin, Eunice S Wang, et al.
Pageof 10